Lucid Diligence Brief: EpilepsyGTx $33m Series A
Lucid Diligence Brief: EpilepsyGTx $33m Series A Professional audiences only.…
Cell and Gene Therapy Today—November 20, 2025
This weekly Cell & Gene Therapy update spans regulatory actions, durable…
ESGCT 2025 Preview: Key Gene & Cell Therapy Highlights to Watch
ESGCT 2025 at a glance Ahead of ESGCT 2025, LucidQuest outlines the…
Cell and Gene Therapy Weekly News - August 28th 2025
🧬 This Week in Gene & Cell Therapy: Rocket Pharma, RMATs, CAR-T…
Cell and Gene Therapy Weekly News - May 22nd 2025
This Week in Gene & Cell Therapy: Personalized CRISPR, FDA Clearances, and…
ASGCT 2025 PREVIEW: Key Cell and Gene Therapy Highlights to Watch
ASGCT 2025 at a glance Count down to ASGCT 2025 with LucidQuest’s brief…
Are AAVs really under threat?
Gene therapies can be the answer to treating, preventing, or curing various…
AAV-based gene therapies: Safe or not? Challenges and considerations for the future.
Adeno-associated virus (AAV) is one of the most studied gene therapy vehicles.…
When it comes to COVID-19, a “nose job” might do the trick
Injectable COVID-19 vaccines may not be the only preventative measure against…